User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC

Primary tabs

download
  • Open access
  • PDF
  • 219.93 K
Leung, Carol Sze Ki Van den Eynde, Benoît [UCL]

In this issue of Cancer Cell, Awad et al. report a phase 1b clinical trial combining a personalized vaccine NEO-PV-01 with chemotherapy and anti-PD-1 pembrolizumab in firstline metastatic non-squamous NSCLC. They demonstrate this treatment regimen was well tolerated and induced neoantigen-specific CD4+ T-cell responses with effector phenotype.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2022
Language Anglais
Journal information "Cancer cell" - Vol. 40, no. 9, p. 903-905 (2022)
Peer reviewed yes
Publisher Cell Press ((United States) Cambridge, MA)
issn 1535-6108
e-issn 1878-3686
Publication status Publié
Affiliation UCL - SSS/DDUV/GECE - Génétique cellulaire
Keywords Cancer Research ; Oncology
Links
Bibliographic reference Leung, Carol Sze Ki ; Van den Eynde, Benoît. Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. In: Cancer cell, Vol. 40, no. 9, p. 903-905 (2022)
Permanent URL http://hdl.handle.net/2078.1/273132